A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Avelumab (Primary) ; Axitinib; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Renal 101
- Sponsors Pfizer
- 24 Jul 2017 Planned number of patients changed from 583 to 830.
- 18 Jul 2017 This trial has been suspended in Austria as per European Clinical Trials Database record.
- 10 Jun 2017 Biomarkers information updated